संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

direct rx - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 100 mg - carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see warnings and precautions (5)] 1.1 osteoarthritis (oa) celecoxib is indicated for relief of the signs and symptoms of oa [see clinical studies (14.1)] 1.2 rheumatoid arthritis (ra) celecoxib is indicated for relief of the signs and symptoms of ra [see clinical studies (14.2)] 1.3 juvenile rheumatoid arthritis (jra) celecoxib is indicated for relief of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3)] 1.4 ankylosing spondylitis (as) celecoxib is indicated for the relief of signs and symptoms of as [see clinical studies (14.4)] 1.5 acute pain (ap) celecoxib is indicated for the management of ap in adults [see clinical studies (14.5)] 1.6 primary dysmenorrhea (pd) celecoxib is indicated for the treatment of pd [see clinical studies (14.5)]

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

direct rx - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine 75 mg - - 1.1 major depressive disorder venlafaxine hydrochloride extended-release capsules, usp are indicated for the treatment of major depressive disorder (mdd). efficacy was established in three short-term (4, 8, and 12 weeks) and two long-term, maintenance trials. 1.3 social anxiety disorder venlafaxine hydrochloride extended-release capsules, usp are indicated for the treatment of social anxiety disorder (sad), also known as social phobia. efficacy was established in four 12-week and one 26-week, placebo-controlled trials. 1.4 panic disorder venlafaxine hydrochloride extended-release capsules, usp are indicated for the treatment of panic disorder (pd), with or without agoraphobia. efficacy was established in two 12-week placebo-controlled trials. venlafaxine hydrochloride extended-release capsules, usp are indicated for the treatment of major depressive disorder (mdd). efficacy was established in three short-term (4, 8, and 12 weeks) and two long-term, maintenance trials. venlafaxine hydrochloride extended

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

direct rx - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 200 mg - carefully consider the potential benefits and risks of celebrex and other treatment options before deciding to use celebrex. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see warnings and precautions (5)] 1.1 osteoarthritis (oa) celebrex is indicated for relief of the signs and symptoms of oa [see clinical studies (14.1)] 1.2 rheumatoid arthritis (ra) celebrex is indicated for relief of the signs and symptoms of ra [see clinical studies (14.2)] 1.3 juvenile rheumatoid arthritis (jra) celebrex is indicated for relief of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3)] 1.4 ankylosing spondylitis (as) celebrex is indicated for the relief of signs and symptoms of as [see clinical studies (14.4)] 1.5 acute pain (ap) celebrex is indicated for the management of ap in adults [see clinical studies (14.5)] 1.6 primary dysmenorrhea (pd) celeb

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

direct rx - diclofenac epolamine (unii: x5f8ekl9zg) (diclofenac - unii:144o8ql0l1) - diclofenac epolamine 180 mg - flector® patch is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions - flector patch is contraindicated in patients with a known hypersensitivity to diclofenac. - flector patch is contraindicated in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.13)]. - flector patch is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1)]. - flector patch is contraindicated for use on non-intact or damaged skin resulting from any etiology, including exudative dermatitis, eczema, infection lesions, burns or wounds. 8.1 pregnancy teratogenic effects pregnancy category c prior to 30 weeks gestation; category d starting 30 weeks gestation. s

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

direct rx - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine 200 mg - 1.1 treatment of hiv-1 infection truvada®, a combination of emtriva® and viread®, is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 17 kg [see dosage and administration (2) and clinical studies (14)]. the following points should be considered when initiating therapy with truvada for the treatment of hiv-1 infection: it is not recommended that truvada be used as a component of a triple nucleoside regimen. truvada should not be coadministered with atripla®, complera®, emtriva, genvoya®, odefsey®, stribild®, viread or lamivudine-containing products [see warnings and precautions (5.4)]. in treatment experienced patients, the use of truvada should be guided by laboratory testing and treatment history [see microbiology (12.4)]. 1.2 pre-exposure prophylaxis truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults a

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

direct rx - methadone hydrochloride (unii: 229809935b) (methadone - unii:uc6vbe7v1z) - methadone hydrochloride 10 mg - - methadone hydrochloride tablets usp are indicated for the:•management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with long-acting opioids, reserve methadone hydrochloride tablets usp for use in patients for whom alternative analgesic treatment options (e.g., non-opioid analgesics or immediate-release opioid analgesics) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. methadone hydrochloride tablets usp are not indicated as an as-needed (prn) analgesic.•detoxification treatment of opioid addiction (heroin or other morphine-like drugs).•maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. conditions

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

direct rx - eszopiclone (unii: uzx80k71oe) (eszopiclone - unii:uzx80k71oe) - eszopiclone tablets are indicated for the treatment of insomnia. in controlled outpatient and sleep laboratory studies, eszopiclone tablets administered at bedtime decreased sleep latency and improved sleep maintenance. the clinical trials performed in support of efficacy were up to 6 months in duration. the final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6 week study (adults only), at the end of both 2 week studies (elderly only) and at the end of the 6 month study (adults only). eszopiclone is contraindicated in patients with known hypersensitivity to eszopiclone. hypersensitivity reactions include anaphylaxis and angioedema [see warnings and precautions (5.3)]. 8.1 pregnancy teratogenic effects: pregnancy category c there are no adequate and well-controlled studies in pregnant women. eszopiclone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral administration of eszopiclone to pregnant rats (62.5, 125, or

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

direct rx - eszopiclone (unii: uzx80k71oe) (eszopiclone - unii:uzx80k71oe) - eszopiclone tablets are indicated for the treatment of insomnia. in controlled outpatient and sleep laboratory studies, eszopiclone tablets administered at bedtime decreased sleep latency and improved sleep maintenance. the clinical trials performed in support of efficacy were up to 6 months in duration. the final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only). eszopiclone tablets are contraindicated in patients with known hypersensitivity to eszopiclone. hypersensitivity reactions include anaphylaxis and angioedema [see warnings and precautions (5.3)]. 8.1 pregnancy pregnancy category c there are no adequate and well-controlled studies in pregnant women. eszopiclone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral administration of eszopiclone to pregnant rats (62.5, 125, or 250 mg/kg/d

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

direct rx - eszopiclone (unii: uzx80k71oe) (eszopiclone - unii:uzx80k71oe) - eszopiclone tablets are indicated for the treatment of insomnia. in controlled outpatient and sleep laboratory studies, eszopiclone tablets administered at bedtime decreased sleep latency and improved sleep maintenance. the clinical trials performed in support of efficacy were up to 6 months in duration. the final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6 week study (adults only), at the end of both 2 week studies (elderly only) and at the end of the 6 month study (adults only). eszopiclone is contraindicated in patients with known hypersensitivity to eszopiclone. hypersensitivity reactions include anaphylaxis and angioedema [see warnings and precautions (5.3)]. 8.1 pregnancy teratogenic effects: pregnancy category c there are no adequate and well-controlled studies in pregnant women. eszopiclone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral administration of eszopiclone to pregnant rats (62.5, 125, or

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

direct rx - eszopiclone (unii: uzx80k71oe) (eszopiclone - unii:uzx80k71oe) - eszopiclone tablets are indicated for the treatment of insomnia. in controlled outpatient and sleep laboratory studies, eszopiclone tablets administered at bedtime decreased sleep latency and improved sleep maintenance. the clinical trials performed in support of efficacy were up to 6 months in duration. the final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only). eszopiclone tablets are contraindicated in patients with known hypersensitivity to eszopiclone. hypersensitivity reactions include anaphylaxis and angioedema [see warnings and precautions (5.3)]. 8.1 pregnancy pregnancy category c there are no adequate and well-controlled studies in pregnant women. eszopiclone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral administration of eszopiclone to pregnant rats (62.5, 125, or 250 mg/kg/d